The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Acute Agitation and Aggression Drugs Market Research Report 2025
Synopsis
With acute agitation and aggression being a common symptom among patients suffering from various types of mental illnesses, the healthcare industry is expending efforts towards developing effective panaceas.
The global Acute Agitation and Aggression Drugs market was valued at US$ 863 million in 2023 and is anticipated to reach US$ 1403.2 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Acute Agitation and Aggression Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Agitation and Aggression Drugs.
Report Scope
The Acute Agitation and Aggression Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Agitation and Aggression Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Agitation and Aggression Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly and Company
Pfizer
Ono Pharmaceutical
Otsuka Holdings
GlaxoSmithKline
Bristol-Myers Squibb
Johnson & Johnson
H. Lundbeck A/S
Segment by Type
Oral
Intramuscular Injection
Others
Segment by Application
Hospitals & Ambulatory Surgical Centers
Psychiatric Care Facilities
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Agitation and Aggression Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
With acute agitation and aggression being a common symptom among patients suffering from various types of mental illnesses, the healthcare industry is expending efforts towards developing effective panaceas.
The global Acute Agitation and Aggression Drugs market was valued at US$ 863 million in 2023 and is anticipated to reach US$ 1403.2 million by 2030, witnessing a CAGR of 7.0% during the forecast period 2024-2030.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
This report aims to provide a comprehensive presentation of the global market for Acute Agitation and Aggression Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Acute Agitation and Aggression Drugs.
Report Scope
The Acute Agitation and Aggression Drugs market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Acute Agitation and Aggression Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Acute Agitation and Aggression Drugs companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Eli Lilly and Company
Pfizer
Ono Pharmaceutical
Otsuka Holdings
GlaxoSmithKline
Bristol-Myers Squibb
Johnson & Johnson
H. Lundbeck A/S
Segment by Type
Oral
Intramuscular Injection
Others
Segment by Application
Hospitals & Ambulatory Surgical Centers
Psychiatric Care Facilities
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Acute Agitation and Aggression Drugs companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Acute Agitation and Aggression Drugs Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Oral
1.2.3 Intramuscular Injection
1.2.4 Others
1.3 Market by Application
1.3.1 Global Acute Agitation and Aggression Drugs Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Hospitals & Ambulatory Surgical Centers
1.3.3 Psychiatric Care Facilities
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Acute Agitation and Aggression Drugs Market Perspective (2019-2030)
2.2 Acute Agitation and Aggression Drugs Growth Trends by Region
2.2.1 Global Acute Agitation and Aggression Drugs Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Acute Agitation and Aggression Drugs Historic Market Size by Region (2019-2024)
2.2.3 Acute Agitation and Aggression Drugs Forecasted Market Size by Region (2025-2030)
2.3 Acute Agitation and Aggression Drugs Market Dynamics
2.3.1 Acute Agitation and Aggression Drugs Industry Trends
2.3.2 Acute Agitation and Aggression Drugs Market Drivers
2.3.3 Acute Agitation and Aggression Drugs Market Challenges
2.3.4 Acute Agitation and Aggression Drugs Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Acute Agitation and Aggression Drugs Players by Revenue
3.1.1 Global Top Acute Agitation and Aggression Drugs Players by Revenue (2019-2024)
3.1.2 Global Acute Agitation and Aggression Drugs Revenue Market Share by Players (2019-2024)
3.2 Global Acute Agitation and Aggression Drugs Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Acute Agitation and Aggression Drugs Revenue
3.4 Global Acute Agitation and Aggression Drugs Market Concentration Ratio
3.4.1 Global Acute Agitation and Aggression Drugs Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Acute Agitation and Aggression Drugs Revenue in 2023
3.5 Acute Agitation and Aggression Drugs Key Players Head office and Area Served
3.6 Key Players Acute Agitation and Aggression Drugs Product Solution and Service
3.7 Date of Enter into Acute Agitation and Aggression Drugs Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Acute Agitation and Aggression Drugs Breakdown Data by Type
4.1 Global Acute Agitation and Aggression Drugs Historic Market Size by Type (2019-2024)
4.2 Global Acute Agitation and Aggression Drugs Forecasted Market Size by Type (2025-2030)
5 Acute Agitation and Aggression Drugs Breakdown Data by Application
5.1 Global Acute Agitation and Aggression Drugs Historic Market Size by Application (2019-2024)
5.2 Global Acute Agitation and Aggression Drugs Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Acute Agitation and Aggression Drugs Market Size (2019-2030)
6.2 North America Acute Agitation and Aggression Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Acute Agitation and Aggression Drugs Market Size by Country (2019-2024)
6.4 North America Acute Agitation and Aggression Drugs Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Acute Agitation and Aggression Drugs Market Size (2019-2030)
7.2 Europe Acute Agitation and Aggression Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Acute Agitation and Aggression Drugs Market Size by Country (2019-2024)
7.4 Europe Acute Agitation and Aggression Drugs Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Acute Agitation and Aggression Drugs Market Size (2019-2030)
8.2 Asia-Pacific Acute Agitation and Aggression Drugs Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Acute Agitation and Aggression Drugs Market Size by Region (2019-2024)
8.4 Asia-Pacific Acute Agitation and Aggression Drugs Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Acute Agitation and Aggression Drugs Market Size (2019-2030)
9.2 Latin America Acute Agitation and Aggression Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Acute Agitation and Aggression Drugs Market Size by Country (2019-2024)
9.4 Latin America Acute Agitation and Aggression Drugs Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Acute Agitation and Aggression Drugs Market Size (2019-2030)
10.2 Middle East & Africa Acute Agitation and Aggression Drugs Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Acute Agitation and Aggression Drugs Market Size by Country (2019-2024)
10.4 Middle East & Africa Acute Agitation and Aggression Drugs Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Eli Lilly and Company
11.1.1 Eli Lilly and Company Company Detail
11.1.2 Eli Lilly and Company Business Overview
11.1.3 Eli Lilly and Company Acute Agitation and Aggression Drugs Introduction
11.1.4 Eli Lilly and Company Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.1.5 Eli Lilly and Company Recent Development
11.2 Pfizer
11.2.1 Pfizer Company Detail
11.2.2 Pfizer Business Overview
11.2.3 Pfizer Acute Agitation and Aggression Drugs Introduction
11.2.4 Pfizer Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.2.5 Pfizer Recent Development
11.3 Ono Pharmaceutical
11.3.1 Ono Pharmaceutical Company Detail
11.3.2 Ono Pharmaceutical Business Overview
11.3.3 Ono Pharmaceutical Acute Agitation and Aggression Drugs Introduction
11.3.4 Ono Pharmaceutical Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.3.5 Ono Pharmaceutical Recent Development
11.4 Otsuka Holdings
11.4.1 Otsuka Holdings Company Detail
11.4.2 Otsuka Holdings Business Overview
11.4.3 Otsuka Holdings Acute Agitation and Aggression Drugs Introduction
11.4.4 Otsuka Holdings Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.4.5 Otsuka Holdings Recent Development
11.5 GlaxoSmithKline
11.5.1 GlaxoSmithKline Company Detail
11.5.2 GlaxoSmithKline Business Overview
11.5.3 GlaxoSmithKline Acute Agitation and Aggression Drugs Introduction
11.5.4 GlaxoSmithKline Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.5.5 GlaxoSmithKline Recent Development
11.6 Bristol-Myers Squibb
11.6.1 Bristol-Myers Squibb Company Detail
11.6.2 Bristol-Myers Squibb Business Overview
11.6.3 Bristol-Myers Squibb Acute Agitation and Aggression Drugs Introduction
11.6.4 Bristol-Myers Squibb Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.6.5 Bristol-Myers Squibb Recent Development
11.7 Johnson & Johnson
11.7.1 Johnson & Johnson Company Detail
11.7.2 Johnson & Johnson Business Overview
11.7.3 Johnson & Johnson Acute Agitation and Aggression Drugs Introduction
11.7.4 Johnson & Johnson Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.7.5 Johnson & Johnson Recent Development
11.8 H. Lundbeck A/S
11.8.1 H. Lundbeck A/S Company Detail
11.8.2 H. Lundbeck A/S Business Overview
11.8.3 H. Lundbeck A/S Acute Agitation and Aggression Drugs Introduction
11.8.4 H. Lundbeck A/S Revenue in Acute Agitation and Aggression Drugs Business (2019-2024)
11.8.5 H. Lundbeck A/S Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
